GlassScriptPhysician profile
Ramin Mazhari
NPI 1811041106
$3,579.84
in general payments reported to CMS, 2019-2025
24 companies · $924 in 2025
The $924 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $121 · 2022: $926 · 2023: $630 · 2024: $979 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,532.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $845.86 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $548.39 | 2022-2025 | |
| Amgen INC. | $308.02 | 2022-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $279.81 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Esperion Therapeutics, INC. | $243.66 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $242.30 | 2022-2025 | |
| Pfizer INC. | $239.00 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $151.33 | 2022 | |
| Daiichi Sankyo INC. | $151.31 | 2024-2025 | Injectafer |
| Bioventus LLC | $83.33 | 2025 | Stimrouter Implantable Kit |
| Providence Medical Technology, INC. | $79.79 | 2022 | |
| Janssen Pharmaceuticals, INC | $64.18 | 2022-2023 | Xarelto |
| Sumitomo Pharma America, INC. | $58.25 | 2024 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $40.51 | 2023-2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $40.27 | 2025 | Recorlev, Gvoke Hypopen |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $36.71 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.91 | 2022 | |
| Abbott Laboratories | $22.67 | 2024 | Freestyle Libre 3 |
| Phadia US INC. | $22.63 | 2025 | Immunocap |
| Astellas Pharma US INC | $21.45 | 2024 | Veozah |
| Exact Sciences Corporation | $20.44 | 2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.77 | 2024 | Jardiance |
| Currax Pharmaceuticals LLC | $16.98 | 2025 | Contrave |
| Ardelyx, INC. | $16.27 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramin Mazhari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.